Previously we found that miR126 was significantly elevated in GBM cells and cell-derived EVs following pan-PAD inhibitor treatment and have in the current study identified that in LN18 cell-derived EVs PAD2 and PAD4 inhibitors were significantly effective in raising relative miR126 expression, while PAD3 specific inhibitor was not effective in increasing relative miR126 expression in LN18 cell-derived EVs. The gene discussed is PADI2; the disease is glioblastoma.